Evidence map›Paper›PMID 30866717›Full record

ArticleCancer biology & therapy2019

Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting.

Ziping Wu, Lei Zhang, Jing Peng, Shuguang Xu, Liheng Zhou, Yanpin Lin, Yan Wang, Jinglu Lu, Wenjin Yin, Jinsong Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ziping Wua Department of Breast Surgery , Renji Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai , China.
Lei Zhanga Department of Breast Surgery , Renji Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai , China.
Jing Penga Department of Breast Surgery , Renji Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai , China.
Shuguang Xua Department of Breast Surgery , Renji Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai , China.
Liheng Zhoua Department of Breast Surgery , Renji Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai , China.
Yanpin Lina Department of Breast Surgery , Renji Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai , China.
Yan Wanga Department of Breast Surgery , Renji Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai , China.
Jinglu Lua Department of Breast Surgery , Renji Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai , China.
Wenjin Yina Department of Breast Surgery , Renji Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai , China.
Jinsong Lua Department of Breast Surgery , Renji Hospital, School of Medicine, Shanghai Jiao Tong University , Shanghai , China.

Funding

EPA EP-C-16-023
6 · The paper itself

Abstract

objectiveProgrammed death-ligand-1 (PDL1) is a molecule involved in immune evasion in various kinds of tumors. Here, we aim to determine whether the expression of PDL1 protein is related to the response of patients to neoadjuvant therapy and survival outcome.

methodsImmunohistochemistry (IHC) was performed on paraffin-embedded tumor samples from core needle biopsy before neoadjuvant therapy (NAT). Univariate and multivariate logistic regression were used to analyze the associations between PDL1 protein expression and pathological complete response (pCR) outcome. Kaplan-Meier plot and log-rank test were used to compare disease-free survival (DFS) between groups. A cox proportional hazards model was used to calculate the adjusted hazard ratio (HR) with 95% confidential interval (95%CI).

resultsA total of 94 patients were included for IHC testing. PDL1 protein expression on tumor cells was associated with better pCR rate in both univariate (OR = 2.621, p = 0.043) and multivariate (OR = 3.595, p = 0.029) logistic regression analysis. It was also associated with shorter DFS both by log-rank test (p = 0.015) and cox hazard model (HR = 22.824, 95%CI 1.621-321.284, p = 0.020). In hormone receptor (HR)-positive patients, PDL1 protein expression was also associated with better pCR (OR = 2.362, p = 0.022). It was also associated with poor DFS (HR = 18.821, 95%CI 1.645-215.330, p = 0.018).

conclusionsOur results show that PDL1 protein expression is a predictive biomarker of pCR and a prognostic factor of DFS in breast cancer patients and HR-positive subgroups.

Indexed as

Gene ExpressionAdultAgedB7-H1 AntigenBreast NeoplasmsFemaleHumansImmunohistochemistryKaplan-Meier EstimateMiddle AgedNeoadjuvant TherapyNeoplasm StagingPrognosisTumor BurdenB7-H1 AntigenCD274 protein, humanBreast cancerneoadjuvantPDL1predictiveprognostic

Identifiers

PMID30866717
PMCPMC6605984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.